JP6138764B2 - ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用 - Google Patents

ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用 Download PDF

Info

Publication number
JP6138764B2
JP6138764B2 JP2014511457A JP2014511457A JP6138764B2 JP 6138764 B2 JP6138764 B2 JP 6138764B2 JP 2014511457 A JP2014511457 A JP 2014511457A JP 2014511457 A JP2014511457 A JP 2014511457A JP 6138764 B2 JP6138764 B2 JP 6138764B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administered
composition according
thiazolide compound
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014511457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513725A5 (enExample
JP2014513725A (ja
Inventor
ロシニョール，ジーン−フランソワ
Original Assignee
ロマーク ラボラトリーズ エル．シー．
ロマーク ラボラトリーズ エル．シー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロマーク ラボラトリーズ エル．シー．, ロマーク ラボラトリーズ エル．シー． filed Critical ロマーク ラボラトリーズ エル．シー．
Publication of JP2014513725A publication Critical patent/JP2014513725A/ja
Publication of JP2014513725A5 publication Critical patent/JP2014513725A5/ja
Application granted granted Critical
Publication of JP6138764B2 publication Critical patent/JP6138764B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F11/00—Rotary presses or machines having forme cylinders carrying a plurality of printing surfaces, or for performing letterpress, lithographic, or intaglio processes selectively or in combination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F13/00—Common details of rotary presses or machines
    • B41F13/08—Cylinders
    • B41F13/18—Impression cylinders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F13/00—Common details of rotary presses or machines
    • B41F13/08—Cylinders
    • B41F13/193—Transfer cylinders; Offset cylinders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F7/00—Rotary lithographic machines
    • B41F7/02—Rotary lithographic machines for offset printing
    • B41F7/025—Multicolour printing or perfecting on sheets or on one or more webs, in one printing unit
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F7/00—Rotary lithographic machines
    • B41F7/02—Rotary lithographic machines for offset printing
    • B41F7/04—Rotary lithographic machines for offset printing using printing units incorporating one forme cylinder, one transfer cylinder, and one impression cylinder, e.g. for printing on webs
    • B41F7/06—Rotary lithographic machines for offset printing using printing units incorporating one forme cylinder, one transfer cylinder, and one impression cylinder, e.g. for printing on webs for printing on sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F7/00—Rotary lithographic machines
    • B41F7/02—Rotary lithographic machines for offset printing
    • B41F7/08—Rotary lithographic machines for offset printing using one transfer cylinder co-operating with several forme cylinders for printing on sheets or webs, e.g. sampling of colours on one transfer cylinder
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41F—PRINTING MACHINES OR PRESSES
    • B41F9/00—Rotary intaglio printing presses
    • B41F9/02—Rotary intaglio printing presses for multicolour printing
    • B41F9/021—Sheet printing presses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014511457A 2011-05-16 2012-05-15 ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用 Expired - Fee Related JP6138764B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486728P 2011-05-16 2011-05-16
US61/486,728 2011-05-16
PCT/US2012/037958 WO2012158699A1 (en) 2011-05-16 2012-05-15 Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017087529A Division JP2017149764A (ja) 2011-05-16 2017-04-26 ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用

Publications (3)

Publication Number Publication Date
JP2014513725A JP2014513725A (ja) 2014-06-05
JP2014513725A5 JP2014513725A5 (enExample) 2015-07-02
JP6138764B2 true JP6138764B2 (ja) 2017-05-31

Family

ID=47175068

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014511457A Expired - Fee Related JP6138764B2 (ja) 2011-05-16 2012-05-15 ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用
JP2017087529A Withdrawn JP2017149764A (ja) 2011-05-16 2017-04-26 ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用
JP2018226678A Pending JP2019052175A (ja) 2011-05-16 2018-12-03 ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017087529A Withdrawn JP2017149764A (ja) 2011-05-16 2017-04-26 ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用
JP2018226678A Pending JP2019052175A (ja) 2011-05-16 2018-12-03 ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用

Country Status (15)

Country Link
US (3) US20120294831A1 (enExample)
EP (1) EP2709453B1 (enExample)
JP (3) JP6138764B2 (enExample)
KR (1) KR102037162B1 (enExample)
CN (2) CN103648282B (enExample)
AU (1) AU2012255962B2 (enExample)
BR (1) BR112013029505A2 (enExample)
CA (1) CA2836253C (enExample)
DK (1) DK2709453T3 (enExample)
EA (1) EA024063B1 (enExample)
ES (1) ES2767304T3 (enExample)
IL (1) IL229459B (enExample)
MX (2) MX2013013115A (enExample)
WO (1) WO2012158699A1 (enExample)
ZA (1) ZA201308617B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017149764A (ja) * 2011-05-16 2017-08-31 ロマーク ラボラトリーズ エル．シー． ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515383A (ja) * 2013-03-15 2016-05-30 ザ・ブロード・インスティテュート・インコーポレイテッド 樹状細胞応答遺伝子発現、組成物およびその使用方法
KR101508610B1 (ko) * 2013-09-02 2015-04-08 가톨릭대학교 산학협력단 다코미티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물
WO2015030504A1 (ko) * 2013-09-02 2015-03-05 가톨릭대학교 산학협력단 비소세포폐암 치료제를 유효성분으로 포함하는 톡소포자충감염증의 예방 또는 치료용 약학 조성물
KR101508611B1 (ko) 2013-09-02 2015-04-08 가톨릭대학교 산학협력단 아파티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물
KR20170081228A (ko) 2014-11-11 2017-07-11 로마크 레버러토리즈, 엘.씨. 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법
US20180098972A1 (en) * 2015-01-26 2018-04-12 Children's Medical Center Corporation Treatment of infectious diseases
HUE050601T2 (hu) 2016-03-31 2020-12-28 Romark Laboratories Lc Tiazolidvegyületek vírusfertõzések kezelésére
PH12018502142B1 (en) 2016-04-11 2023-08-11 Genfit Methods of treatment for cholestatic and fibrotic diseases
CN105998036B (zh) * 2016-05-19 2018-07-27 洛阳市兽药厂 一种猪禽用复方磺胺硝唑尼特可溶性粉
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
AU2018368611B2 (en) * 2017-11-17 2023-12-14 KÖSTER, Hubert (2-((5-nitro-1,3-thiazol-2-yl)carbamoyl)phenyl)ethanoate for use in lymphangioleiomyomatosis and other diseases
MA55597A (fr) * 2019-04-12 2022-02-16 Genfit Nitazoxanide et thiazolides destinés à être utilisés dans le traitement de maladies associées au stress oxydatif
WO2021021563A1 (en) 2019-07-26 2021-02-04 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
CN113398125B (zh) 2020-03-16 2024-05-03 绍兴君科臻元医药科技有限公司 替唑尼特药物组合物及其医药用途
EP4182304A1 (en) 2020-07-20 2023-05-24 Romark Laboratories, L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
CN116367892A (zh) 2020-08-24 2023-06-30 罗马克实验室有限公司 噻唑化物抗冠状病毒的用途
AU2022209835A1 (en) 2021-01-25 2023-09-14 Espervita Therapeutics, Inc. Functionalized long-chain carboxylic acids, and their use for treatment of disease
WO2022159811A1 (en) * 2021-01-25 2022-07-28 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
WO2023077711A1 (zh) * 2021-11-03 2023-05-11 南方科技大学 预防前列腺癌的药剂的筛选方法及硝唑尼特在制药中的应用
CN114231611A (zh) * 2021-12-07 2022-03-25 中南大学湘雅二医院 干扰素诱导基因ifit3对b淋巴细胞活化及分化影响的研究方法
CN116539887A (zh) * 2023-01-09 2023-08-04 重庆医科大学 Psme1作为药物靶点在筛选或制备治疗乙型肝炎的药物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) * 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
US5965590A (en) * 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5958038A (en) * 1997-11-07 1999-09-28 S3 Incorporated Computer processor with two addressable memories and two stream registers and method of data streaming of ALU operation
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
WO2006110814A2 (en) 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
CN101448497B (zh) * 2006-01-09 2013-07-10 罗马克实验室有限公司 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用
CA2707247A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
US20100081713A1 (en) * 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
TWI729512B (zh) * 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
KR20180032689A (ko) * 2009-06-26 2018-03-30 로마크 레버러토리즈, 엘.씨. 인플루엔자를 치료하기 위한 화합물 및 방법
US20110020272A1 (en) * 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
WO2011049825A1 (en) * 2009-10-22 2011-04-28 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20110223131A1 (en) * 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US9439878B2 (en) * 2010-06-03 2016-09-13 Douglas Tyler McKenzie Use of lumefantrine and related compounds in the treatment of cancer
EP2725902A4 (en) * 2011-04-06 2015-06-24 Univ Princeton ANTIVIRAL COMBINATION THERAPY
MX2013013115A (es) * 2011-05-16 2014-02-27 Romark Lab Lc Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017149764A (ja) * 2011-05-16 2017-08-31 ロマーク ラボラトリーズ エル．シー． ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用

Also Published As

Publication number Publication date
IL229459B (en) 2021-05-31
US20190291404A1 (en) 2019-09-26
CN103648282A (zh) 2014-03-19
WO2012158699A1 (en) 2012-11-22
EP2709453A1 (en) 2014-03-26
KR102037162B1 (ko) 2019-10-29
AU2012255962B2 (en) 2016-05-12
MX2013013115A (es) 2014-02-27
US10336058B2 (en) 2019-07-02
CN107096032A (zh) 2017-08-29
DK2709453T3 (da) 2020-01-20
CA2836253C (en) 2021-02-16
MX378726B (es) 2025-03-11
KR20140028034A (ko) 2014-03-07
CA2836253A1 (en) 2012-11-22
JP2014513725A (ja) 2014-06-05
EA201391616A1 (ru) 2014-05-30
EA024063B1 (ru) 2016-08-31
EP2709453A4 (en) 2014-11-19
JP2017149764A (ja) 2017-08-31
JP2019052175A (ja) 2019-04-04
US20180126722A1 (en) 2018-05-10
ES2767304T3 (es) 2020-06-17
EP2709453B1 (en) 2019-10-23
IL229459A0 (en) 2014-01-30
US20120294831A1 (en) 2012-11-22
ZA201308617B (en) 2020-07-29
CN103648282B (zh) 2017-02-15
BR112013029505A2 (pt) 2020-01-07
US10814612B2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
JP6138764B2 (ja) ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用
AU2012255962A1 (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
Holicek et al. Type I interferon and cancer
Sabbaghi et al. Role of γδ T cells in controlling viral infections with a focus on influenza virus: implications for designing novel therapeutic approaches
JP2023011840A (ja) 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
JP2013522302A (ja) 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療
JP2025169407A (ja) ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
Bergman et al. Interferons as therapeutic agents for infectious diseases
AU2018211247B2 (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
TW202348237A (zh) TLR8調節化合物及抗HBV siRNA療法之組合
HK1240084A1 (en) A method of stimulating an immune response in a subject in need thereof
HK1192415A (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
HK1192415B (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
Dec et al. Use of oromucosally administered IFN-α in the prevention and treatment of animal diseases
AU746648B2 (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
Poulas Imiquimod-A Toll like Receptor 7 Agonist-IS an Ideal Option for Management of COVID 19
Offersen et al. A TLR9-agonist adjuvant induces cellular memory in response to pneumococcal conjugate vaccine in HIV-infected adults
Schröder et al. Human DEAD-box protein 3 enhances pattern-recognition receptor-induced IFN-beta production and is a target for viral manipulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160923

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170426

R150 Certificate of patent or registration of utility model

Ref document number: 6138764

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees